Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CJC-1295 (with DAC) | Hexarelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 2 mg administered once weekly via subcutaneous injection. | Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release. | On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks between cycles. | 4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs. |
| Evidence Level | moderate_human | moderate_human |
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.
Research indicates 2 mg administered once weekly via subcutaneous injection.
Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.
12-24 week cycles with 4-8 week breaks between cycles.
Hexarelin (Examorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent synthetic GH secretagogue by peak GH release. It stimulates GH release through both pituitary ghrelin receptors and hypothalamic pathways, with mechanisms involving regulation of GHRH and somatostatin. Hexarelin also demonstrates significant cardiac benefits through activation of cardiac GHS-R1a receptors, protecting against ischemia-reperfusion injury and reducing cardiac fibrosis via the CD36 scavenger receptor pathway.
Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection.
On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization.
4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →